Every material Form 8-K TG Therapeutics filed with the SEC in 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TG Therapeutics reported results for the third quarter ended September 30, 2023, with total revenue of $165.8 million, of which $140.0 million was a one-time payment from Neuraxpharm. The company reported net income of $113.9 million, compared with a net loss of $35.8 million a year earlier, and said cash, cash equivalents and investment securities were $229.2 million at quarter end.
Q3 2023 total revenue of $165.8 million, including $140.0 million of license revenue tied to a one-time Neuraxpharm payment received in July 2023
BRIUMVI U.S. net sales of $25.1 million in Q3 2023, up from $0.1 million in Q3 2022
Q3 2023 net income of $113.9 million, or $0.80 per basic share, versus a net loss of $35.8 million in Q3 2022
Cash, cash equivalents and investment securities of $229.2 million as of September 30, 2023
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TG Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →